Divesting Patents: The Substance Behind the Optics
Conventional wisdom holds that patents are best left on the shelf as visible signals of strength. To investors, and R&D bean counters, patents are presented as intangible assets ֊ talismanic rights that project the aura of defence, warding off evil competitors and even non-practicing entities (NPEs). The narrative is that a “paper-weight” portfolio creates a dense field, repelling attacks and shoring up confidence.
But this depiction is largely illusory. Patents are not shields in the physical sense. They are rights to exclude, exercised only through litigation or negotiation. An NPE with no products to infringe is not dissuaded by the size of a portfolio; it is only deterred by the practical resources, legal posture, and contractual rights the company can assert in response. The protective spell often ascribed to patents is perception more than function.
This is where divestment takes on importance. Holding for optics creates the appearance of security but drains resources on maintenance fees, prosecution costs, and administrative burden. More pragmatic companies prune their portfolios on a routine basis, composting patents tied to obsolete research paths. Investors often view such pruning not as weakness, but as discipline, a signal that management treats intellectual property as a managed asset, not a vanity metric.
There is also the matter of revenue. Patents that no longer serve the business can be monetized. A sale converts dormancy into capital, sometimes substantial returns, without diluting equity. Divestment demonstrates agility: management recognizes when an asset’s highest value lies outside the firm. For investors, this is evidence of sound corporate strategy.
Get Logendra Naidoo’s stories in your inbox
Join Medium for free to get updates from this writer.
Divestment does not mean your business is infirm or that it means you need cash flow. It’s sound business logic. Furthermore, well-structured sale agreements can preserve defences through covenants not to sue, license-backs, or springing licenses that activate if the buyer sells to a hostile. Some contracts even include reciprocal provisions: if the buyer sues, rights revert or countermeasures apply. In practice, the company parts with the patent but not with the practical shield. The repellant effect remains, only now coupled with liquidity and contractual control. The gist is, “We know what we’re doing with our IP, so if you sue us, be forewarned, we are good at strategic decision-making.”
Investors also weigh the optics of portfolio size. While zero patents on the books may not be favourable, an active IP program demonstrates pruning discipline, reinvests proceeds into R&D, and shows that divestment agreements preserve ownership benefits. For example, a company may sell patents yet retain rights to develop products as if it still owned them, or include terms that allow the patents to be used defensively against specific competitors should litigation arise (i.e., a springing license triggered by defined counterparties). These contractual safeguards restore lost rights in practice, reassuring investors that divestment does not equal disarmament.
Patents, as property rights, possess what might be called magical properties. They can be sold yet retained in part; granted in title yet bounded in use. To outside observers, it may appear a company has surrendered an asset. In reality, the terms can tether that asset back, preserving security while releasing capital. Outside parties who see a portfolio reduced in size would be unwise to assume financial strain; such moves are a way of lining a company’s coffers while at the same time lining its defences.
Examples matter. BlackBerry, for instance, waited too long. By the time it sold significant portions of its portfolio, its handset business had lost its edge in a market reshaped by Apple, Samsung, and others. What could have been strategic monetization looked more like distressed liquidation. Investors saw missed returns rather than foresight. IBM and Intel, by contrast, have been more systematic, pruning regularly and divesting non-core patents while their value remained high, showing how planned divestiture can reinforce investor trust rather than erode it.
BlackBerry’s delayed sales illustrate how waiting erodes potential returns; earlier divestment could have captured significantly higher value for shareholders.
Divestment should not be construed as weakening investor confidence but building it. The illusion of protection created by hoarding is an antiquated belief that fails to recognize the tangible advantages of generating revenue, fostering discipline, and maintaining strategic flexibility. Patents impress in number, but they build lasting investor trust when actively managed, sometimes pruned, sometimes monetized, sometimes sold with strings attached.
